D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first-in-human (FIH) trial design.

被引：0
|
作者：
Lu, Jingtao [1 ]
Zhang, Jing [1 ]
Zheng, Zhiqiang [1 ]
Chen, Cheng [1 ]
Wang, Jia [1 ]
Chen, Janet [1 ]
Lu, Jiang [1 ]
Rui, Haopeng [1 ]
Wang, Allison [1 ]
Chen, Zhi Jian [1 ]
机构：
[1] D3 Bio Wuxi Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15087
引用
收藏
页数：1
相关论文
共 18 条
  • [1] Preclinical characterization of D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C.
    Zhang, Jing
    Wu, Wentao
    Xu, Yangyang
    Qian, Yi
    Xia, Yuanfeng
    Lu, Jiang
    Zheng, Zhiqiang
    Lu, Jingtao
    Chen, Janet
    Chen, Chase
    Wang, Jia
    Chen, Cheng
    Rui, Haopeng
    Wang, Allison
    Jin, John
    Chen, Zhi Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
    Cho, B. C.
    Shen, Y.
    Li, Z.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Liu, Y.
    Rui, H.
    Chen, J. Q.
    Wang, A. H.
    Zhang, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1642 - S1643
  • [3] A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress).
    Ammakkanavar, Natraj Reddy
    Call, Justin
    Shimizu, Toshio
    Kuboki, Yasutoshi
    Liu, Shiyao
    Willard, Melinda D.
    Axelson, Michael
    Heist, Rebecca S.
    Patnaik, Amita
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics
    Zhang, J.
    Lu, J.
    Zheng, Z.
    Lu, J.
    Wang, A.
    Wang, J.
    Chen, J.
    Rui, H.
    Chen, C.
    Chen, G.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S74 - S74
  • [5] A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
    Murciano-Goroff, Yonina R.
    Heist, Rebecca S.
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Ammakkanavar, Natraj Reddy
    Hollebecque, Antoine
    Patnaik, Amita
    Shimizu, Toshio
    Spira, Alexander I.
    Nagasaka, Misako
    Han, Ji-Youn
    Iams, Wade Thomas
    Deming, Dustin
    Call, Justin
    Cassier, Philippe
    Han, Sae-Won
    Chu, Quincy Siu-Chung
    Cosman, Rasha
    Durm, Gregory
    Burns, Timothy
    Willard, Melinda D.
    Liu, Shiyao
    Callies, Sophie
    Balar, Arjun V.
    Sabari, Joshua K.
    CANCER RESEARCH, 2023, 83 (08)
  • [6] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
    Cho, B. C.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Li, Z.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Wang, J.
    Chen, J.
    Wang, A.
    Zhang, J.
    Chen, Z. G.
    Mok, T. S. K.
    Johnson, M. L.
    ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
  • [7] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [8] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
  • [9] D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
    Zhang, Jing
    Lim, Sun Min
    Yu, Mi Ra
    Chen, Cheng
    Wang, Jia
    Wang, Wenqian
    Rui, Haopeng
    Lu, Jingtao
    Lu, Shun
    Mok, Tony
    Chen, Zhi Jian
    Cho, Byoung Chul
    CANCER DISCOVERY, 2024, 14 (09) : 1675 - 1698
  • [10] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
    Li, Jian
    Zhao, Jun
    Cao, Baoshan
    Fang, Jian
    Li, Xiaoyan
    Wang, Mengzhao
    Ba, Yi
    Li, Xingya
    Li, Zhihua
    Liu, Zhe
    Wang, Yongsheng
    Cheng, Ying
    Bai, Chunmei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12